Patient selection, ventricular tachycardia substrate
delineation, and data transfer for stereotactic arrhythmia
radioablation: a clinical consensus statement of the European
Heart Rhythm Association of the European Society of Cardiology
and the Heart Rhythm Society

J 2025

Patient selection, ventricular tachycardia substrate delineation, and data transfer for stereotactic arrhythmia radioablation: a clinical consensus statement of the European Heart Rhythm Association of the European Society of Cardiology and the Heart Rhythm Society

ZEPPENFELD, Katja; Robert RADEMAKER; Amin AL-AHMAD; Corrado CARBUCICCHIO; De Chillou CHRISTIAN et. al.

Základní údaje

Originální název

Patient selection, ventricular tachycardia substrate delineation, and data transfer for stereotactic arrhythmia radioablation: a clinical consensus statement of the European Heart Rhythm Association of the European Society of Cardiology and the Heart Rhythm Society

Autoři

Vydání

EP Europace, Oxford, Oxford University Press, 2025, 1099-5129

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30201 Cardiac and Cardiovascular systems

Stát vydavatele

Velká Británie a Severní Irsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 7.400 v roce 2024

Organizační jednotka

Lékařská fakulta

DOI

https://doi.org/10.1093/europace/euae214

UT WoS

001478856200001

EID Scopus

2-s2.0-105003938289

Klíčová slova anglicky

Ventricular tachycardia; Stereotactic arrhythmia radioablation (STAR); Sudden death; Radiotherapy; Ablation

Štítky

14110211, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 3. 6. 2025 13:09, Mgr. Tereza Miškechová

Anotace

V originále

Stereotactic arrhythmia radioablation (STAR) is a novel, non-invasive, and promising treatment option for ventricular arrhythmias (VAs). It has been applied in highly selected patients mainly as bailout procedure, when (multiple) catheter ablations, together with anti-arrhythmic drugs, were unable to control the VAs. Despite the increasing clinical use, there is still limited knowledge of the acute and long-term response of normal and diseased myocardium to STAR. Acute toxicity appeared to be reasonably low, but potential late adverse effects may be underreported. Among published studies, the provided methodological information is often limited, and patient selection, target volume definition, methods for determination and transfer of target volume, and techniques for treatment planning and execution differ across studies, hampering the pooling of data and comparison across studies. In addition, STAR requires close and new collaboration between clinical electrophysiologists and radiation oncologists, which is facilitated by shared knowledge in each collaborator's area of expertise and a common language. This clinical consensus statement provides uniform definition of cardiac target volumes. It aims to provide advice in patient selection for STAR including aetiology-specific aspects and advice in optimal cardiac target volume identification based on available evidence. Safety concerns and the advice for acute and long-term monitoring including the importance of standardized reporting and follow-up are covered by this document. Areas of uncertainty are listed, which require high-quality, reliable pre-clinical and clinical evidence before the expansion of STAR beyond clinical scenarios in which proven therapies are ineffective or unavailable.

Citovat

ZEPPENFELD, Katja; Robert RADEMAKER; Amin AL-AHMAD; Corrado CARBUCICCHIO; De Chillou CHRISTIAN; Jakub CVEK; Micaela EBERT; Gordon HO; Josef KAUTZNER; Pier LAMBIASE; Jose Luis MERINO; Michael LLOYD; Satish MISRA; Etienne PRUVOT; John SAPP; Luis SCHIAPPACASSE; Marek SRAMKO; William G STEVENSON; Paul C ZEI; Dan WICHTERLE; Jonathan CHRISPIN; Claudia Herrera SIKLODY; Radek NEUWIRTH; Gemma PELARGONIO; Tobias REICHLIN; Clifford ROBINSON a Claudio TONDO. Patient selection, ventricular tachycardia substrate delineation, and data transfer for stereotactic arrhythmia radioablation: a clinical consensus statement of the European Heart Rhythm Association of the European Society of Cardiology and the Heart Rhythm Society. EP Europace. Oxford: Oxford University Press, 2025, roč. 27, č. 4, s. 1-33. ISSN 1099-5129. Dostupné z: https://doi.org/10.1093/europace/euae214.

@article{2501037,
   author = {Zeppenfeld, Katja and Rademaker, Robert and AlandAhmad, Amin and Carbucicchio, Corrado and Christian, De Chillou and Cvek, Jakub and Ebert, Micaela and Ho, Gordon and Kautzner, Josef and Lambiase, Pier and Merino, Jose Luis and Lloyd, Michael and Misra, Satish and Pruvot, Etienne and Sapp, John and Schiappacasse, Luis and Sramko, Marek and Stevenson, William G and Zei, Paul C and Wichterle, Dan and Chrispin, Jonathan and Siklody, Claudia Herrera and Neuwirth, Radek and Pelargonio, Gemma and Reichlin, Tobias and Robinson, Clifford and Tondo, Claudio},
   article_location = {Oxford},
   article_number = {4},
   doi = {https://doi.org/10.1093/europace/euae214},
   keywords = {Ventricular tachycardia; Stereotactic arrhythmia radioablation (STAR); Sudden death; Radiotherapy; Ablation},
   language = {eng},
   issn = {1099-5129},
   journal = {EP Europace},
   title = {Patient selection, ventricular tachycardia substrate delineation, and data transfer for stereotactic arrhythmia radioablation: a clinical consensus statement of the European Heart Rhythm Association of the European Society of Cardiology and the Heart Rhythm Society},
   url = {https://academic.oup.com/europace/article/27/4/euae214/7739845?login=true},
   volume = {27},
   year = {2025}
}

TY  - JOUR
ID  - 2501037
AU  - Zeppenfeld, Katja - Rademaker, Robert - Al-Ahmad, Amin - Carbucicchio, Corrado - Christian, De Chillou - Cvek, Jakub - Ebert, Micaela - Ho, Gordon - Kautzner, Josef - Lambiase, Pier - Merino, Jose Luis - Lloyd, Michael - Misra, Satish - Pruvot, Etienne - Sapp, John - Schiappacasse, Luis - Sramko, Marek - Stevenson, William G - Zei, Paul C - Wichterle, Dan - Chrispin, Jonathan - Siklody, Claudia Herrera - Neuwirth, Radek - Pelargonio, Gemma - Reichlin, Tobias - Robinson, Clifford - Tondo, Claudio
PY  - 2025
TI  - Patient selection, ventricular tachycardia substrate delineation, and data transfer for stereotactic arrhythmia radioablation: a clinical consensus statement of the European Heart Rhythm Association of the European Society of Cardiology and the Heart Rhythm Society
JF  - EP Europace
VL  - 27
IS  - 4
SP  - 1-33
EP  - 1-33
PB  - Oxford University Press
SN  - 10995129
KW  - Ventricular tachycardia
KW  - Stereotactic arrhythmia radioablation (STAR)
KW  - Sudden death
KW  - Radiotherapy
KW  - Ablation
UR  - https://academic.oup.com/europace/article/27/4/euae214/7739845?login=true
N2  - Stereotactic arrhythmia radioablation (STAR) is a novel, non-invasive, and promising treatment option for ventricular arrhythmias (VAs). It has been applied in highly selected patients mainly as bailout procedure, when (multiple) catheter ablations, together with anti-arrhythmic drugs, were unable to control the VAs. Despite the increasing clinical use, there is still limited knowledge of the acute and long-term response of normal and diseased myocardium to STAR. Acute toxicity appeared to be reasonably low, but potential late adverse effects may be underreported. Among published studies, the provided methodological information is often limited, and patient selection, target volume definition, methods for determination and transfer of target volume, and techniques for treatment planning and execution differ across studies, hampering the pooling of data and comparison across studies. In addition, STAR requires close and new collaboration between clinical electrophysiologists and radiation oncologists, which is facilitated by shared knowledge in each collaborator's area of expertise and a common language. This clinical consensus statement provides uniform definition of cardiac target volumes. It aims to provide advice in patient selection for STAR including aetiology-specific aspects and advice in optimal cardiac target volume identification based on available evidence. Safety concerns and the advice for acute and long-term monitoring including the importance of standardized reporting and follow-up are covered by this document. Areas of uncertainty are listed, which require high-quality, reliable pre-clinical and clinical evidence before the expansion of STAR beyond clinical scenarios in which proven therapies are ineffective or unavailable.
ER  -

ZEPPENFELD, Katja; Robert RADEMAKER; Amin AL-AHMAD; Corrado CARBUCICCHIO; De Chillou CHRISTIAN; Jakub CVEK; Micaela EBERT; Gordon HO; Josef KAUTZNER; Pier LAMBIASE; Jose Luis MERINO; Michael LLOYD; Satish MISRA; Etienne PRUVOT; John SAPP; Luis SCHIAPPACASSE; Marek SRAMKO; William G STEVENSON; Paul C ZEI; Dan WICHTERLE; Jonathan CHRISPIN; Claudia Herrera SIKLODY; Radek NEUWIRTH; Gemma PELARGONIO; Tobias REICHLIN; Clifford ROBINSON a Claudio TONDO. Patient selection, ventricular tachycardia substrate delineation, and data transfer for stereotactic arrhythmia radioablation: a clinical consensus statement of the European Heart Rhythm Association of the European Society of Cardiology and the Heart Rhythm Society. \textit{EP Europace}. Oxford: Oxford University Press, 2025, roč.~27, č.~4, s.~1-33. ISSN~1099-5129. Dostupné z: https://doi.org/10.1093/europace/euae214.

Přehled o publikaci